These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25962992)

  • 1. Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).
    Morales J; Merker L
    Adv Ther; 2015 May; 32(5):391-403. PubMed ID: 25962992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Opin Drug Saf; 2017 Mar; 16(3):387-396. PubMed ID: 28150516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
    Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
    Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
    Harris K; Nealy KL
    Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
    Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
    Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
    Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
    Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
    Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Price H; Blüher M; Prager R; Phan TM; Thorsted BL; Schultes B;
    Diabetes Obes Metab; 2018 Apr; 20(4):954-962. PubMed ID: 29205856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
    Lisco G; De Tullio A; Guastamacchia E; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
    Lamos EM; Davis SN
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1225-32. PubMed ID: 27467569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
    Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
    Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
    Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
    J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
    Hughes E
    Prim Care Diabetes; 2016 Jun; 10(3):202-9. PubMed ID: 26776758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
    Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
    Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K; Peene B; Mathieu C
    Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
    Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
    Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.